Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston blog main
boston top stories
clinical trials
4
×
life sciences
national blog main
national top stories
4
×
patisiran
4
×
akcea therapeutics
alnylam pharmaceuticals
boston
fda
hereditary transthyretin amyloidosis
inotersen
new york blog main
new york top stories
rna interference
san diego blog main
san diego top stories
tafamidis
biotech
drugs
onpattro
pfizer
san francisco blog main
san francisco top stories
vyndaqel
alexion pharmaceuticals
andrew fire
anylam pharmaceuticals
barry greene
boehringer ingelheim
boston university
cardiomyopathy
craig mello
dan ollendorf
deals
dicerna pharamceuticals
hepatitis b
hepatitis b virus
john berk
What
alnylam
drug
fda
ago
approved
disease
medicine
medicines
patients
pharmaceuticals
afternoon
akcea
alnylam’s
amyloidosis
approve
attr
available
awaits
battle
biological
caught
causing
crossed
debilitating
decades
decision
dicerna
discovered
eye
fingers
friday
gene
genetic
gets
hepatitis
historic
history
intended
landmark
making
Language
unset
Current search:
patisiran
×
" clinical trials "
×
" national top stories "
×
@xconomy.com
4 years ago
Roche to Pay Dicerna Pharma $200M to Team Up on Hepatitis B Drug
@xconomy.com
5 years ago
FDA OKs Pfizer Rare Disease Drug, Sets Up Battle With Alnylam, Akcea
@xconomy.com
5 years ago
Alnylam Gets Landmark FDA OK For First-Ever RNAi Drug
@xconomy.com
5 years ago
Patients Have “Fingers Crossed” As Alnylam Awaits Historic FDA Decision